CYTOPROTECTOR MILDRONATE IN CORRECTING MYOCARDIAL DYSFUNCTION AMONG STABLE ANGINA PATIENTS AFTER CORONARY REVASCULARISATION
Abstract
In total, 149 patients, aged 41–75 years, with Functional Class (FC) II-III stable angina, who underwent coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI), were examined. Group I (n=79) received standard therapy, as well as post-intervention mildronate therapy (750 mg/day for three days, then 750 mg per day twice a week). Group II (79 controls) did not receive any metabolic medications. Total and local left ventricular (LV) myocardial contractility was assessed by echocardiography 10–15 days before, 2–3 days before, and 10–12 days after the revascularisation. Mildronate therapy was associated with total and local myocardial contractility improvement, observed even before the intervention and further increasing after the operation. It was also linked to the reduction in post-revascularisation, reperfusionrelated LV myocardial dysfunction.
About the Authors
I. G. Gordeev
ГОУ ВПО Российский государственный медицинский университет Росздрава, Москва
Russian Federation
Russian Federation
E. E. Luchinkina
ГОУ ВПО Российский государственный медицинский университет Росздрава, Москва
Russian Federation
Russian Federation
S. V. Hegay
ГОУ ВПО Российский государственный медицинский университет Росздрава, Москва
Russian Federation
Russian Federation
References
1. Калвиньш И.Я. Милдронат: механизм действия и перспективы его применения // Рига, ПАО «Гриндекс», 2002.
2. Лечение стабильной стенокардии. Рекомендации специальной комиссии Европейского общества кардиологов // Прил. РМЖ, т.2,№ 1, 1998.
3. Маколкин В.И. Ишемическая дисфункция миокарда и пути ее коррекции // Ишемическая болезнь сердца, № 2, 2000.
4. Маколкин В.И., Осадчий К.К. Роль миокардиальной цитопротекции в оптимизации лечения ишемической болезни сердца // Consilium Medicum. № 5, том 6, 2004, с.304–307.
5. Astein C.S. Изменение основного энергетического субстрата миокарда, как способ защиты от ишемического повреждения: результаты, полученные в клинике // Медикография.-1999.- Вып.60.-Т.21.-№ 2.-с. 13–20.
6. Colombo A., Hall P., Nakamura S. et al. Introcoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance // Circulation, 1995, 91: pp. 1676–1688.
7. Ferreira R., Burgos M., Llesuy S. et al. Reduction of reperfusion injury with mannitol cardioplegia // Ann.Thorac.Surg. 1989;48:77– 84.
8. Lopaschuk GD et al. Оптимизация метаболизма сердечной мышцы: новый подход к лечению ишемической болезни сердца? // Медикография 1999, том 21, № 2:21–28.
9. Medical and Cellular Implications f Stunning, Hibernation, and Preconditioning // Circulation.1998;97:1848–1867.
10. Rahimtoola S.H. The hibernating myocardium // Am. Heart J. 1989;117:211–221.
11. Ramos C.L., Pou S., Brigitan B.E. et al. Spin trapping evidence for myeloperoxidase- dependent hydroxyl radical formation by human neutrophils and monocyte // J Biol-Chem 1992; 267:8307–8312.
12. Schiller N.B., Shah P.M., Crawford M. et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography //J.Am.Soc.Echocardiography. – 1989. – Vol.2. – P.358–367.
13. Taegtmeyer H. Energy substrate metabolism, myocardial ischaemia and target for pharmacotherapy // Am.J.Cardiol. 1998;82:54K- 60K.
Review
For citations:
Gordeev I.G., Luchinkina E.E., Hegay S.V. CYTOPROTECTOR MILDRONATE IN CORRECTING MYOCARDIAL DYSFUNCTION AMONG STABLE ANGINA PATIENTS AFTER CORONARY REVASCULARISATION. Russian Journal of Cardiology. 2009;(2):54-58. (In Russ.)
Views:
627
Email this article 